Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;19(1):51-9.
doi: 10.3350/cmh.2013.19.1.51. Epub 2013 Mar 25.

A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience

Myung Jin Oh  1 , Heon Ju Lee
Affiliations

A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience

Myung Jin Oh et al. Clin Mol Hepatol. 2013 Mar.

Abstract

Background/aims: The widespread use of cytotoxic chemotherapy and immunosuppressants has resulted in reactivation of hepatitis B virus (HBV) recently becoming an issue. Although rituximab (an anti-CD20 monoclonal antibody) has revolutionized the treatment of lymphoma, recent reports have suggested that rituximab therapy increases the risk of viral-mediated complications, and particularly HBV reactivation. This study analyzed real clinical practice data for rituximab-related HBV reactivation.

Methods: Between January 2005 and December 2011, 169 patients received treatment with rituximab. Screening status of the HBV infection and frequency of preemptive therapy were determined in these patients, and the clinical features of HBV reactivation were analyzed.

Results: Seventy-nine of the 169 patients with chronic or past HBV infection were selected for evaluation of HBV reactivation. Of the 90 patients who were excluded, 22 (13.0%) were not assessed for HBsAg and anti-HBc, and 14 (8.3%) were not assessed for anti-HBc due to seronegativity for HBsAg. The selected patients were divided into those with chronic HBV infection (n=12) and those with past HBV infection (n=67); six patients (7.6%) experienced HBV reactivation. Eight patients received preemptive therapy, but three patients (37.5%) underwent HBV reactivation. Although HBsAg seropositivity was an independent risk factor for HBV reactivation (P=0.038), of the six patients with HBV reactivation, two (33.3%) had past HBV infection and three (50%) died of liver failure.

Conclusions: The findings of this study demonstrate that adherence to guidelines for screening and preemptive therapy for HBV reactivation was negligent among the included cohort. Attention should be paid to HBV reactivation in patients with past as well as chronic HBV infection during and after rituximab therapy.

Keywords: Hepatitis B virus; Immunosuppressant; Rituximab.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts to disclose.

Figures

Figure 1
Figure 1
Flow chart of the enrolled patients.
See this image and copyright information in PMC

References

    1. Lai CL, Yuen MF. Chronic hepatitis B--new goals, new treatment. N Engl J Med. 2008;359:2488–2491. - PubMed
    1. Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica. 2010;95:135–143. - PMC - PubMed
    1. Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2009;9:10–25. - PubMed
    1. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209–220. - PubMed
    1. Watanabe M, Shibuya A, Tsunoda Y, Danbara M, Ishii R, Ohsaka M, et al. Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection. Liver Int. 2011;31:340–347. - PubMed

MeSH terms

LinkOut - more resources